Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b open-label PK/PD study of IZD174 in Parkinson's disease
NL-OMON49465Phase 1Active, not recruiting
- Sponsor
- Inflazome
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of inzomelid in Parkinson's disease (PD) (3 arms), sponsored by Inflazome. Primary endpoints: CSF to plasma concentration ratio, CSF to plasma AUC ratios and 1 more. Started Mar 2020; status: active, not recruiting.
02
Drugs
inzomelid
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON49465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49465.